1. Home
  2. OLMA vs DGICB Comparison

OLMA vs DGICB Comparison

Compare OLMA & DGICB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • OLMA
  • DGICB
  • Stock Information
  • Founded
  • OLMA 2006
  • DGICB 1986
  • Country
  • OLMA United States
  • DGICB United States
  • Employees
  • OLMA 88
  • DGICB N/A
  • Industry
  • OLMA Biotechnology: Pharmaceutical Preparations
  • DGICB Property-Casualty Insurers
  • Sector
  • OLMA Health Care
  • DGICB Finance
  • Exchange
  • OLMA Nasdaq
  • DGICB Nasdaq
  • Market Cap
  • OLMA 465.4M
  • DGICB 504.0M
  • IPO Year
  • OLMA 2020
  • DGICB N/A
  • Fundamental
  • Price
  • OLMA $5.92
  • DGICB $15.06
  • Analyst Decision
  • OLMA Strong Buy
  • DGICB
  • Analyst Count
  • OLMA 5
  • DGICB 0
  • Target Price
  • OLMA $26.25
  • DGICB N/A
  • AVG Volume (30 Days)
  • OLMA 1.0M
  • DGICB 928.0
  • Earning Date
  • OLMA 11-12-2024
  • DGICB 10-24-2024
  • Dividend Yield
  • OLMA N/A
  • DGICB 4.12%
  • EPS Growth
  • OLMA N/A
  • DGICB 148.60
  • EPS
  • OLMA N/A
  • DGICB 0.74
  • Revenue
  • OLMA N/A
  • DGICB $979,119,004.00
  • Revenue This Year
  • OLMA N/A
  • DGICB N/A
  • Revenue Next Year
  • OLMA N/A
  • DGICB $5.78
  • P/E Ratio
  • OLMA N/A
  • DGICB $21.91
  • Revenue Growth
  • OLMA N/A
  • DGICB 7.44
  • 52 Week Low
  • OLMA $6.10
  • DGICB $10.75
  • 52 Week High
  • OLMA $16.78
  • DGICB $16.81
  • Technical
  • Relative Strength Index (RSI)
  • OLMA 23.84
  • DGICB 59.65
  • Support Level
  • OLMA $6.25
  • DGICB $14.26
  • Resistance Level
  • OLMA $6.87
  • DGICB $15.90
  • Average True Range (ATR)
  • OLMA 0.82
  • DGICB 0.53
  • MACD
  • OLMA -0.34
  • DGICB -0.02
  • Stochastic Oscillator
  • OLMA 0.00
  • DGICB 31.38

About OLMA Olema Pharmaceuticals Inc.

Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.

About DGICB Donegal Group Inc. Class B

Donegal Group Inc is an insurance holding company that offers businesses and individuals personal and commercial lines of property and casualty insurance. The company's reportable segments are its Investment function, Personal lines of insurance, and Commercial lines of insurance. Personal lines products consist mainly of homeowners and private passenger automobile policies. The Commercial lines products of its insurance subsidiaries consist mainly of commercial automobile, commercial multi-peril, and workers' compensation policies. The group mainly operates in the United States.

Share on Social Networks: